Articles

Poll

Podcasts

Slideshows

Videos

Ophthalmology

Ophthalmology page, resources on the topics of medical news and expert insight into ophthalmic disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on eye disease research, treatment, and drug development.

At ARVO 2023, 24-month data suggests the change from baseline in GA lesion growth consistently favored pegcetacoplan vs. sham across subgroups in DERBY and OAKS trials.

Analysis Suggests Consistent Efficacy of Pegcetacoplan on GA Lesion Growth

In an interview at ARVO 2023, Danzig discusses the post-hoc analysis from the GATHER trials, showing that a reduced rate of vision loss in patients receiving avacincaptad pegol was correlated with reduced GA growth. 

Carl Danzig, MD: Analysis of GATHER Trials Connects GA Growth with Vision Loss 

At ARVO 2023, Caroline Baumal, MD, chief medical officer of Apellis Pharmaceuticals, discussed new phase 3 functional analyses of pegcetacoplan injection, the future of the GA treatment landscape, and the next unmet need in ophthalmology. 

Caroline Baumal, MD: Marking a New Treatment Era for GA with Pegcetacoplan

As part of our ARVO 2023 coverage, Dr. Sheth sat down with Pravin Dugel, MD, President of Iveric Bio to discuss avacincaptad pegol for geographic atrophy and a look back at Dr. Dugel's career and his transition into industry. 

New Insight: A Look at Avacincaptad Pegol with Pravin Dugel, MD

Eyes treated with pegcetacoplan showed a significantly slower GA lesion progression rate compared with sham, and slower growth rate toward the fovea.

Geographic Atrophy